EMA Authorised: Agamree (vamorolone) — Santhera Pharmaceuticals (Deutschland) GmbH

View source ↗

Summary

The European Medicines Agency authorised Agamree (vamorolone) by Santhera Pharmaceuticals for Duchenne muscular dystrophy, with orphan medicine designation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• AGAMREE (Vamorolone)

Snippet

Status: Authorised. Therapeutic area: Muscular Dystrophy, Duchenne. MAH: Santhera Pharmaceuticals (Deutschland) GmbH. Decision date: 08/04/2026. Orphan medicine